Clinical-stage biopharmaceutical company focused on epilepsy; leader in ion channel drug discovery and development

SANIONA PRESENTATION, Q1 2024

Disclaimer

This company presentation (the ”**Company Presentation**”), which is personal to the recipient, is issued by Saniona AB (the “**Company**”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of independent judgement. The Company Presentation may not be reproduced, redistributed, passed on or published, in whole or in part, to any other person for any purpose. Unless otherwise stated, the Company is the source for all data contained in the Company Presentation. Such data is provided as at the date of this Company Presentation and is subject to change without notice. The Company Presentation (together with any further information which may be provided to the addressee) is made available on the condition that it is for use only by the addressee specified above for the sole purpose of evaluating the Company and shall not be passed on to any other person or copied or reproduced, copied, distributed, disclosed or published in whole or part and shall be immediately returned along with any other copies or destroyed at any time at the request of Company.

The Company Presentation is solely for your information and should not be relied upon and shall not confer rights or remedies upon, you or any of your employees, creditors, holders of securities or other equity holders or any other person. No representation or warranty, express or implied, is made by the Company or any of its directors, officers, employees, representatives, advisers or agents or any other person or entity as to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, whichever its source, contained in this document (including any written or oral information made available to any interested party in connection thereto), and no liability whatsoever is accepted by any such person in relation to any such information or opinion. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its credit worthiness and does not purport to be all-inclusive or to contain all information that prospective investors may desire or that may be required to properly evaluate the business, prospects or value of the Company.

The information in this Company Presentation has not been independently verified. No representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. The Company or any of their respective subsidiaries or affiliates or any of such person’s directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this Company Presentation or otherwise arising in connection therewith. The Company is under no obligation to submit further information. By receiving this Company Presentation and/or attending a presentation concerning the contents hereof you acknowledge that you will be solely responsible for your own assessment of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company.

This Company Presentation includes forward-looking statements. All statements other than statements of historical fact included in this Company Presentation, including, without limitation, those regarding the Company’s financial position, business strategy, management plans and objectives for future operations are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this Company Presentation and the Company expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this Company Presentation as a result of any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.

saniona

Experienced Board of Directors and Management

Board of Directors

Jörgen Drejer
Chairman

Anna Ljung
Board member

Carl Johan Sundberg
Board member

Pierandrea Muglia
Board member

Management

Thomas Feldthus
Co-founder and CEO

Anita Milland
CFO

Janus Schreiber Larsen
CDO

Karin Sandager Nielsen
CSO

Palle Christophersen
Executive VP, Research

Saniona Investment Highlights

- Expanding pipeline in collaboration with partners - Tesofensine targeting market launch in 2024 together with partner, Tesomet (phase 2b), SAN711 (phase 2a) and SAN903 (phase 1) and several pre-clinical assets available for partnering
- Cutting-edge proprietary ion channel drug discovery engine – continuous value creation through generation of new high potential drug candidates for epilepsy and other CNS indications
- Platform validated by leading pharmaceutical companies – SEK +400m received through successful spinouts, partnerships, and licensing agreements with upside potential preserved
- Potential near-term income from partnerships - research funding from existing partnerships, potential milestones, royalty income from tesofensine, new partnering opportunities on clinical assets and platform
- Focused epilepsy pipeline addressing indications with significant medical need including SAN711 (phase 2 POC ready) for potential internal development partly financed through partnership income

Successful partnership history – platform validated by several leading pharmaceutical companies

Partnerships and spinouts		Income (SEKm)	Future Upside
2023	AstronauTx	R&D collaboration/license	~4	Milestones + royalties
	Cephagenix	Joint Venture	~4	33% ownership
	Boehringer Ingelheim	R&D collaboration/license	~20	Milestones + royalties
	PROXIMAGEN	R&D collaboration/license	~20	Regained program
	Boehringer Ingelheim	R&D collaboration/license	~111	Regained program
	SCANDION ONCOLOGY	Spinout (shareholding sold)	~126	
	medix	License (tesofensine)	~25	Milestones + royalties
	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH	Grants	~8	
	Initiator Pharma	Spinout distributed to shareholders		Milestones + royalties
	Pfizer	R&D collaboration/license	~16	Regained program
	CADENT Therapeutics > NOVARTIS	Spinout + R&D collaboration	~53	Earnout + royalties
2012	janssen	R&D collaboration/license	~17	Regained program
		Total Income (SEKm)	**~404**	

saniona

Expanding pipeline of new drug candidates with solid scientific rationale

Product Candidate	Indication	Research	LOP/CS	Pre-clinical	Phase 1	Phase 2a	Phase 2b	Phase 3	Comment
Tesofensine	Obesity								**Potential market launch 2024** – partnership with market leader **Medix**, representing near-term revenue potential through mid-teens royalties and milestone
Tesomet	HO, PWS								**Positioned for partnering** following successful phase 2a data (2019)
SAN711	Epilepsy								**Positioned for absence seizures** following positive phase 1 data (2022). Value-inflection points in 2024/25
SAN903	Fibrotic and inflammatory								**Positioned for partnering** following successful IND/CTA enabling studies
SAN2219	Epilepsy								**Positioned for acute repetitive seizures** with multiple expansion opportunities in rare and severe epilepsy
SAN2355	Epilepsy								**Positioned for focal/generalized epilepsy** and paediatric epilepsy
SAN2465	Depressive disorder								**Positioned for partnering** following candidate selection for rapid onset major depressive disorder
GABA program	Epilepsy								**Positioned for rare pediatric epilepsy syndrome** with multiple expansion opportunities in rare and severe epilepsy
AstronauTx	Alzheimer's								Partnership agreement entitling Saniona to **milestone payments of up to USD 177m plus royalties**
Boehringer Ingelheim	Schizophrenia								Partnership agreement entitling Saniona to **milestone payments of up to EUR 76.5m plus royalties**
Cephagenix	Migraine								Joint venture, Saniona owns 33%

saniona

Saniona poised for success in epilepsy

- Focused epilepsy pipeline addressing indications with significant medical need
- Selective ion-channel modulators maximize efficacy and minimize adverse effects
- Precision medicines addressing underlying pathology with disease modifying potential
- Predictive preclinical models and innovative clinical study design with objective endpoints and on-target biomarkers enhance success rate
- Experienced team with deep expertise in CNS and ion-channel drug discovery and development including GABA PAMs and Kv7 activators

Epilepsy – large market driven by new products addressing significant unmet medical need

- >20 approved Anti Seizure Medications (ASM) – mostly generics
- Top 10 branded ASM accounted for 80% of sales in 2022[1]
- Top branded products and companies expected to change within 5 years[1]
- 30% drug resistant >1.5 million patients in 7 Major Markets
- Paediatric Syndromes, often drug resistant to broad spectrum ASM, have devastating life-long consequences for patients and families
- Recently introduced ASMs demonstrate that market remains interesting for products addressing unmet medical needs
  - For adults with generalized/focal onset seizure: Xcopri/Ontozry (SK BIO) and XEN1101 (Xenon) in phase 3 are expected to reach more than USD 1B and USD 750m respectively in 2028
  - For paediatric Orphan Diseases: Epidiolex (Jazz) and Finteplay (UCB) are expected to reach USD 1.2B and USD 800m respectively in 2028

Global Epilepsy Market

50 million
People affected by epilepsy worldwide[2]
>6 million people in the US and EU[3,4]

30%
Resistant to existing therapies[5]

>4%
Annual growth[6]

USD 8 billion market
By 2028[6]

1) Evaluate pharma; 2) World Health Organization; 3) CDC statistics for 2015: Epilepsy Data and Statistics | CDC; 4) Evaluate Pharma; 5) Kwan et al 2000 New England Journal of Medicine; Chen et al 2018 JAMA Neurology; 6) Evaluate Pharma, estimated growth 2022-2028.

saniona

Epilepsy has been subject to several recent deals

Investor	Target	Deal	Year	Transaction size	Comment
UCB	ZOGENIX	Acquisition	2022	USD 1.9 billion	Worldwide rights to fenfluramine (Fintepla®) for the treatment of seizures associated with Dravet syndrome
Jazz Pharmaceuticals	GW pharmaceuticals	Acquisition	2021	USD 7.2 billion	Worldwide rights to cannabidiol (Epidiolex®) for the treatment of seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex
ANGELINI PHARMA	ARVELLE THERAPEUTICS	Acquisition	2021	USD 960 million	EU rights of cenobamate (Ontozry®) for the treatment of drug-resistant focal-onset seizures in adults
Takeda	ovid THERAPEUTICS	Collaboration	2017	USD 856 million	Total payments of up to USD 856 million incl. USD 196 million upfront and tiered double-digit Royalties on sales for Soticlestat*

*Soticlestat is a Takeda small molecule in Phase 3 development for Paediatric OD indications – Ovid conducted Phase 2 under a collaboration with Takeda for two orphan diseases (Dravet Syndrome and Lennox-Gastaut)

saniona

Subtype selective $GABA_A$ PAMs: maximizing efficacy, minimizing adverse events

$GABA_A$ POSITIVE ALLOSTERIC MODULATORS (PAMs):

- Highly effective anti-epileptics but dose-limited by adverse effects
- Modulates all $GABA_A$ receptors ($\alpha1$, $\alpha2$, $\alpha3$ and $\alpha5$) non-selectively
- $GABA_A$ $\alpha1$ pharmacology drives major adverse events: sedation, cognitive impairment, abuse liability and tolerance development (reduced effectiveness over time)
- Saniona assets designed to exert highly differentiated pharmacology, specifically tailored to address the unmet needs of specific indications
- Retaining strong seizure control while avoiding the use-limitations associated with non-selective $GABA_A$ PAMs



Therapeutic effect of benzodiazepines	$GABA_A$ $\alpha1$	$GABA_A$ $\alpha2$	$GABA_A$ $\alpha3$	$GABA_A$ $\alpha5$
Anti-seizure	++	++	++	
Analgesia		++	++	
Anxiolysis		++	+	
Sedation	++			
Tolerance	++			
Addiction	++	+		
Cognitive impair.	++			+

PAM: Positive Allosteric Modulator

Mohler H Diversity in neuronal inhibition, Dial. Clin. Neurosci. 2002; Knabl J, Reversal of pathological pain through specific spinal GABAA receptor subtypes, Nat. Lett. 2008 ; Rudolph U et al., Beyond classical benzodiazepines, novel therapeutic potential of GABAA receptor subtypes, Nat.Rev. Drug Discov. 2012

saniona

Saniona $GABA_A$ PAMs: differentiated pharmacology tailored to address unmet need in specific indications

SAN711:
Precision medicine for absence seizures devoid of liability for attentional impairment and birth defects

Therapeutic effect	$GABA_A$ α1	$GABA_A$ α2	$GABA_A$ α3	$GABA_A$ α5
Anti-seizure	++	++	++	
Analgesia		++	++	
Anxiolysis		++	+	
Sedation	++			
Tolerance	++			
Addiction	++	+		
Cog. impair	++			+

CNS adverse effects

Target for SAN711

SAN2219:
Strong seizure control devoid of $GABA_A$ α1 use limitations for acute repetitive seizures

$GABA_A$ α1	$GABA_A$ α2	$GABA_A$ α3	$GABA_A$ α5
++	++	++	
	++	++	
	++	+	
++			
++			
++	+		
++			+

Target for SAN2219

GABA program:
Strong seizure control with additional antiseizure efficacy to treat severe pediatric syndrome

$GABA_A$ α1	$GABA_A$ α2	$GABA_A$ α3	$GABA_A$ α5
++	++	++	
	++	++	
	++	+	
++			
++			
++	+		
++			+

Target for GABA program

PAM: Positive Allosteric Modulator

Mohler H Diversity in neuronal inhibition, Dial. Clin. Neurosci. 2002; Knabl J, Reversal of pathological pain through specific spinal GABAA receptor subtypes, Nat. Lett. 2008 ; Rudolph U et al., Beyond classical benzodiazepines, novel therapeutic potential of GABAA receptor subtypes, Nat.Rev. Drug Discov. 2012

saniona

Epilepsy Pipeline

Product Candidate	Indication	Expansion opportunity	Research	LOP/CS	Pre-clinical	Phase 1	Phase 2	Status
SAN711 GABA α3 PAM	Absence seizures	Generalized idiopathic epilepsy						Positive Phase 1 data reported w/ target engagement imaging biomarker
SAN2219 *GABA α2/3/5 PAM*	On demand repetitive seizures	Refractory Focal onset epilepsy						Ready for Preclinical Development
GABA program *GABA α1/2/3/5 PAM*	Rare pediatric DEE-SWAS syndrome	Rare genetically defined loss of function mutations						Ready for Preclinical Development
SAN2355 Kv7.2/Kv7.3	Refractory Focal onset epilepsy	Rare genetically defined seizures						Lead Optimization / Candidate selection



LOP: Lead Optimization Phase
CS: Candidate selection
DEE-SWAS: Developmental Epileptic Encephalopathy with Spike Wave activation during Slow wave sleep

saniona

Portfolio of precision medicines for epilepsy indications with significant unmet medical need and potential to be first approved and/or first-in-class therapies

Pipeline asset	SAN711	SAN2219	GABA program	SAN2355
Indication	**Absence seizures (CAE + JAE)**	**Acute on demand seizure control (ARS)**	**Developmental epileptic encephalopathy with Spike Wave activation during sleep (DEE-SWAS)**	**Treatment refractory focal onset seizures**
Prevalent population	**CAE, US*: 47-80K (add: 16-26K)** **JAE, US*: 60-90K (add: 40-60K)**	**> 300K*****	**2.4-7K (US)***	**FOS, US**: 1.8M (add: 600K)**
Potential Market position	**First-in-class** Potential to become first-line based on highly differentiated profile	**First-in-class** Differentiated profile vs. approved Benzodiazepines	**First approved treatment** Rare pediatric syndrome with high unmet need	**Best-in-class** Differentiated profile vs. XEN1101
Key therapeutic value proposition	Precision pharmacology targeting the root cause of the disease pathophysiology without attentional impairment and embryofetal risk	Acute on demand remedy devoid of benzodiazepine use limitations incl. restrictions on treatment frequency	Precision pharmacology targeting the root cause of the seizure physiology with potential to prevent neurodevelopmental disabilities. Devoid of high-dose benzodiazepine- and steroid use limitations	Precision pharmacology reestablishing neuronal inhibition with limited CNS adverse effects, urinary retention problems and retinal abnormalities
Mechanism	$GABA_A$ α3 PAM targeting SWDs to prevent absence seizures	$GABA_A$ α2/α3/α5 PAM reestablishing neuronal inhibition to arrest cluster seizures	$GABA_A$ α2/α3/α5 PAM targeting SWDs and reestablishing neuronal inhibition in relevant brain circuits	Kv7.2/Kv7.3 activator selectively dampening neuronal hyperexcitability in relevant circuits

Add: Addressable patients; ARS: Acute repetitive seizures; CAE: childhood absence epilepsy; JAE: juvenile absence epilepsy; DEE: Developmental epileptic encephalopathy; FOS: Focal onset seizures; PAM: positive allosteric modulator; SWDs: Spike-Wave-Discharges
*Saniona sponsored Market analysis (Back Bay Life Science Advisors lead indication report aug-oct 2020); **CDC statistics for 2015: Epilepsy Data and Statistics | CDC and assuming 30% difficult to treat; ***Mesraoua et al J. Drug Assess, 2021,

saniona

Potential first-in-class precision medicine for treatment of absence seizures

SAN711

- **ABSENCE SEIZURES** – short episodes of impairment of consciousness caused by aberrant Spike-Wave-Discharges
- First line therapy impairs cognition and carries risk for women of childbearing potential
- Characteristics of Absence seizures[1]
  - Cause short period of “blanking out”/staring into space
  - Person suddenly stops all activity
  - Eyes may turn upwards and eyelids flutter
  - Seizures usually last <10 seconds
  - Majority of absence seizures begin during childhood, most commonly from age 4 – 14

Up to 10%
Of all childhood epilepsy[2]

20%
Are drug resistant[2]

40%
Continue to have seizures into adulthood[2]

33%
Have cognitive impairment (attention deficits)[2]

1) epilepsy.com/what-is-epilepsy/seizure-types/absence-seizures; 2) Trinka E et al., Absences in adult seizure disorders. Acta Neurol Scand 2005, Physiol Rev. vol 103, 2023; Glauser T.A et al ., Ethosuximide valproate and lamotrigine in childhood absence epielpsy New Engl. J. Med. 2010

saniona

Precision medicine by selectively targeting disease pathophysiology

Strong effects in a highly predictable rodent model for absence seizures

SAN711

- Robust effects obtained in two independent studies (academia and CRO)
- SAN711 precision pharmacology prevents absence seizures by abolishing SWDs in specific brain networks
- No detrimental effects on cognition is anticipated
- Specific contribution of $GABA_A$ $\alpha3$ in SWD prevention established[1,2]





n = 11 per condition / #**/***/**** p < 0.05/0.01/0.001 as compared to vehicle (two way RM ANOVA, post hoc Fishers test)
Data averaged between 70 and 190 min after administration and normalized for baseline values.

Therapeutic effect	$GABA_A$ $\alpha1$	$GABA_A$ $\alpha2$	$GABA_A$ $\alpha3$	$GABA_A$ $\alpha5$
Anti-seizure	++	++	++	
Analgesia		++	++	
Anxiolysis		++	+	
Sedation	++			
Tolerance	++			
Addiction	++	+		
Cog. impair	++			+

Target for SAN711

1) Duveau et al., CNS neurosci. Ther. 2019; 2) https://ir.avenuetx.com/news-events/press-releases/detail/73/avenue-therapeutics-announces-high-potency-and-full

saniona

Innovative trial design for Proof of Concept

Objective Endpoint with Dose Selected based on Target Engagement Biomarker

SAN711

- PoC– Single Country (BE) - multi-centre (Brussels, Leuven, Gent)
  - Double-blind, placebo controlled, parallel-group study to assess Effect on EEG and Absence Seizures using a validated device[1]
- N=15 patients randomized 2:1
  - Active dose selected based on available PK-RO data (PET Imaging Target Engagement)
  - ~2-week titration + 2-week maintenance period





1) Swinnen et al. Accurate Detection of Typical Absence Seizures in Adults and Children Using a Two Channel EEG Wearable. Epilepsia 2021

saniona

Focused profile targeting $GABA_A$ a2 and a3 receptors: a clear differentiating potential vs. current standard of care for acute, on demand seizures control devoid of use limitations

SAN2219

- **ACUTE REPETITIVE SEIZURES (ARS)** are bouts of seizures over a short period of time despite preventive antiseizure medication
- Can evolve into status epilepticus if not arrested
- Benzodiazepines are most common treatment for ARS
- Use of benzodiazepines are restricted due to GABAA a1 driven adverse effects
- SAN2219 focused profile provide strong seizure control by potent GABAA a2 and a3 potentiation
- Synergistic effects demonstrated when combined with Standard-of-care with different mode-of-actions, indicting ability to arrest break-through seizures
- No use limitations anticipated due to lack of GABAA a1 activation

Rodent model	Seizure type	Activity
6 Hz test	Focal seizures	✓
PTZ threshold test	Generalized myoclonic seizures	✓
MEST test	Generalized Tonic Clonic seizures	✓
PTZ bolus test	Absence seizures	✓

MEST: Maximal electroshock threshold test; PTZ: Pentylenetetrazole

Therapeutic effect	$GABA_A$ α1	$GABA_A$ α2	$GABA_A$ α3	$GABA_A$ α5
Anti-seizure	++	++	++	
Analgesia		++	++	
Anxiolysis		++	+	
Sedation	++			
Tolerance	++			
Addiction	++	+		
Cog. impair	++			+

Target for SAN2219

https://www.epilepsyfoundationmn.org/2020/01/14/acute-repetitive-seizures-ars-or-cluster-seizures/, NICE National Institute for Health and Care Excellence

saniona

Balanced pharmacology optimized for additional seizure control

Potential to be the first approved treatment for SWAS

GABA program

- **SPIKE-WAVE ACTIVATION DURING SLEEP (SWAS)** – rare infant onset syndrome with no approved treatment
- Results in cognitive- and developmental regression
- Successful early treatment improve cognitive and developmental outcome
- Highly resistant to standard of care with benzodiazepines, steroids or brain surgery
- GABA program targeting the root cause of the seizure physiology and concurrently
- Potential to prevent neurodevelopmental disabilities
- Devoid of high-dose benzodiazepine- and steroid use limitations

Rodent model	Seizure type	Activity
6 Hz	Focal seizures	✓
PTZ threshold test	Generalized myoclonic seizures	✓
PTZ bolus test	Absence seizures	✓

PTZ: Pentylenetetrazole

Therapeutic effect	$GABA_A$ α1	$GABA_A$ α2	$GABA_A$ α3	$GABA_A$ α5
Anti-seizure	++	++	++	
Analgesia		++	++	
Anxiolysis		++	+	
Sedation	++			
Tolerance	++			
Addiction	++	+		
Cog. impair	++			+

Target for GABA program

SWAS: spike-wave activation during Sleep

Baumer FM et al., Treatment practices and outcomes in CSWS: a multicenter collaboration, J. Pediatr. 2022

saniona

Saniona Kv7 activators: Unique subtype selective Kv7.2-7.3 activators with potential to be devoid of dose-limiting CNS adverse effects and blue discolorations

SAN2355

Kv7 ACTIVATORS:

- Non-selective activators proven effective in treatment refractory focal onset epilepsy (Retigabine, Trobalt®/Ezogabine®)
- Withdrawn in 2017: blue discoloring of skin, retinal abnormalities caused by unstable chemistry, urinary retention, CNS adverse effects
- Saniona´s subtype selective assets shows unique differentiated profiles with strong antiseizure control maintained while adverse effect profiles superior to non-selective comparators
- New chemistry avoiding unstable metabolite (blue discolorations)

	Kv7.1	Kv7.2	Kv7.3	Kv7.4	Kv7.5
Regulator of neuronal activity in the brain		++	++		+
Regulator of electrical activity in the heart	++				
Regulator of bladder smooth muscle cell activity				++	+

AE: adverse effects, Brickel et al., Epilep. Behav. 2020; Ioannou P et al., Brain Behav. 2022, Kwan P et al., Epilepsia 2010, Laxer KD et al., Epilepsia and Behavior 2014, https://www.neurologylive.com/view/anticonvulsant-potiga-discontinued-june-2017

saniona

Unique selective activator of Kv7.2-7.3 subtypes

Differentiated pharmacology with strong seizure control and superior adverse effect profile

SAN2355

- **DRUG REFRACTORY FOCAL ONSET EPILEPSY** evades standard antiseizure medication
- 30 % unable to achieve seizure freedom
- Severely increases the disease burden:
  - increased premature mortality, increased morbidity, lower quality of life than controlled epilepsy
- Kv7 Program unique selectivity profile retaining strong anti-seizure activity while avoiding CNS- urinary retention adverse effects and adverse events caused by metabolic instability (retinal- and skin discoloration)

Rodent model	Seizure type	Activity
6 Hz	Focal seizures	✓
MEST test	Generalized Tonic Clonic seizures	✓

Asset	Fold difference between effect and CNS AEs*
XEN1101	approx. 2-4
Kv7 program	Approx. 25

*Fold difference in free plasma concentration between efficacious doses and doses causing CNS adverse effects

	Kv7.1	Kv7.2	Kv7.3	Kv7.4	Kv7.5
Regulator of neuronal activity in the brain		++	++		+
Regulator of electrical activity in the heart	++				
Regulator of bladder smooth muscle cell activity				++	+

Target for Kv7 program

Urinary retention

CNS AEs

CNS: Central Nervous System; AE: Adverse Effec; Ioannou P et al., Brain Behav. 2022, Kwan P et al., Epilepsia 2010, Laxer KD et al., Epilepsia and Behavior 2014, https://www.neurologylive.com/view/anticonvulsant-potiga-discontinued-june-2017

saniona

Advancing current epilepsy pipeline – potential to close valuation gap to peers



Comment
Dopamine agonist for Parkinson's (Phase 3) and **GABA 2/3 PAM** (Darigabat) for epilepsy (Phase 2)
Glutamate program for ataxia and OCD (Phase 3) and **Kv7 program** for epilepsy and bipolar disorder (Phase 1)
Kv7 program (X1101) for focal onset seizures (Phase 3)
GABA and NMDA platform for various indications and clinical stages. **Old GABA PAM** (steroid) product recently approved for postpartum depression
Ganaxolone, **old GABA PAM** (steroid), for various epilepsy indications incl. CDKL5 disorder (approved), Status Epilepticus (Phase 3), Tuberous Sclerosis (Phase 3)
Partner (Takeda) in Phase 3 for epilepsy syndrome Internal programs in Phase 1 or pre-clinical
Na blocker and type-T calcium channel blocker in Phase 1/2 for epilepsy and essential tremors
Three GABA PAM programs (SAN711 (phase 2 ready), SAN2219 (preclinical), GABA program (preclinical) **and a Kv7 program** (SAN2355, preclinical)

1) Capitaliq.com, As per close 2023-10-27

GABA and Kv7 ion channel compounds expected to outgrow the Epilepsy market

- Saniona's GABA-program and Kv7-program have potential to provide significant value
- Development of GABA and Kv7-program prioritized by Saniona
- Current Kv7-programs highly valued
  - Xenon's Phase 3 Kv7-program XEN1101 – NPV of USD 2 billion[1]
  - Biohaven's Phase 1 Kv7-program – NPV of USD 795 million[2]

GABA & Kv7 ion channel compounds combined market size[3] (USD billion)



Epilepsy market 2021



Epilepsy market 2028



1) Evaluate Pharma, Company | Xenon Pharmaceuticals | Report, 2023-10-17; 2) Evaluate Pharma, Company | Biohaven | Report, 2023-10-17; 3) Evaluate Pharma, Market Value by MoA, 2023-10-17

Eating disorders candidates – targeting market launch and partnering

- **Tesofensine** – targeting market launch 2024
  - Q1 2023 Mexican regulatory authority expressed favorable opinion[1] for treatment of obesity
  - Partnership – market leader Medix
    - Near-term revenue potential in 2024
  - Initially targeting obesity market in Mexico with potential to expand into other territories

Mexican obesity market

- **75%** of Mexican people are obese or overweight[2]
  - → Huge unmet need
- **USD 190m** by 2023[3]
- **16%** CAGR[3]

- **Tesomet** – positioned for partnering following successful phase 2a data (2019)
- Orphan designated drug targeting two rare diseases
  - Hypothalamic obesity (HO)
    - Impacts up to 65,000 people in the US and EU[4,5,6]
  - Prader-Willi syndrome (PWS)
    - Impacts up to 84,000 people in the US and EU[7,8]

1) "Saniona's partner Medix receives favorable opinion for tesofensine for the treatment of obesity and weight management in Mexico"; 2) 2018 data on Mexico by ENSANUT (the National Survey on Health and Nutrition); 3) Medix estimates; 4) Bunin et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg, 89 547-551 (1998). doi:10.3171/jns.1998.89.4.0547; 5) Zacharia et al. Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro-Oncology, 14 1070-1078. (2012). doi:10.1093/neuonc/nos142; 6) NIH GARD: rarediseases.info.nih.gov/diseases/6463/hypothalamic-obesity; 7) Manzardo et al. Survival trends from the Prader–Willi Syndrome Association (USA) 40-year mortality survey, Genet Med 20, 24–30 (2018) doi:10.1038/gim.2017.92; 8) National organization of Rare Diseases: rarediseases.org/rare-diseases/prader-willi-syndrome/

Saniona Investment Highlights

- Expanding pipeline in collaboration with partners - Tesofensine targeting market launch in 2024 together with partner, Tesomet (phase 2b), SAN711 (phase 2a) and SAN903 (phase 1) and several pre-clinical assets available for partnering
- Cutting-edge proprietary ion channel drug discovery engine – continuous value creation through generation of new high potential drug candidates for epilepsy and other CNS indications
- Platform validated by leading pharmaceutical companies – SEK +400m received through successful spinouts, partnerships, and licensing agreements with upside potential preserved
- Potential near-term income from partnerships - research funding from existing partnerships, potential milestones, royalty income from tesofensine, new partnering opportunities on clinical assets and platform
- Focused epilepsy pipeline addressing indications with significant medical need including SAN711 (phase 2 POC ready) for potential internal development partly financed through partnership income

saniona™

Thank You